Records containing: Metastatic Renal Cell Carcinoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2017-04-04A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
-
CLINICAL_TRIALS study record update · 2017-03-22Phase I/II Study of Increasing Doses of Lutetium-177 Labeled Chimeric Monoclonal Antibody cG250 (177^Lu-DOTA-cG250) in Patients With Advanced Renal Cancer
-
CLINICAL_TRIALS study record update · 2017-03-10Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
-
CLINICAL_TRIALS study record update · 2016-07-26Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma
-
CLINICAL_TRIALS study record update · 2016-06-02An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2016-05-18Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2016-05-17A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients
-
CLINICAL_TRIALS study record update · 2016-03-01A Randomized Phase II Trila of Sunitinib Four-weeks on/Two-weeks Off Versus Two-weeks on/One-week Off as First Line Therapy in Metastatic Renal Cell Carcinoma.
-
CLINICAL_TRIALS study record update · 2016-01-18A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN-2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL CARCINOMA
-
CLINICAL_TRIALS study record update · 2016-01-05A SU011248 Expanded Access Protocol for Metastatic RCC Patients Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
-
CLINICAL_TRIALS study record update · 2015-12-01A Phase II Study of VEGF Blockade With Bevacizumab Combined With Autologous Tumor/Dendritic Cell Vaccine (DC Vaccine), Interleukin-2 (IL-2) and Interferon-α-2b (IFNα-2b) in Patients With Metastatic Renal Cell Carcinoma (RCC)
-
CLINICAL_TRIALS study record update · 2015-11-23Pilot Study to Evaluate the Feasibility of Functional MRI in Metastatic Renal Cell Carcinoma (mRCC) With Test--retest Repeatability and Early Response Assessment
-
CLINICAL_TRIALS study record update · 2015-11-06An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
-
CLINICAL_TRIALS study record update · 2015-10-12A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intratumorally in Patients With Metastatic Renal Cell Carcinoma
-
CLINICAL_TRIALS study record update · 2015-10-06Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC Study) Impact of Adverse Events Management in Elderly mRCC Patients Treated With Sorafenib
-
CLINICAL_TRIALS study record update · 2015-09-17Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
-
CLINICAL_TRIALS study record update · 2015-04-30Etude Resume (Retraitement Sunitinib Rein Metastatique)
-
CLINICAL_TRIALS study record update · 2015-04-01A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy
-
CLINICAL_TRIALS study record update · 2015-03-26Patterns Of Care Among Australian Cohort Of Patients With Advanced Rrc Receiving Sutent
-
CLINICAL_TRIALS study record update · 2014-12-02A Randomized Phase II Trial of IL-2/IFN-α Plus Bevacizumab Versus IL-2/IFN-α in Metastatic Renal Cell Carcinoma (mRCC) - Danish Renal Cancer Group (DARENCA) Study-1
-
CLINICAL_TRIALS study record update · 2014-09-25A Randomized Phase II Trial Of Sunitinib Administered Daily For 4 Weeks, Followed By 2-Week Rest Vs. 2-Week On And 1-Week Off In Metastatic Renal Cell Carcinoma
-
CLINICAL_TRIALS study record update · 2014-06-18Phase II Single Arm Study of IMC-1121B in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy
-
CLINICAL_TRIALS study record update · 2014-03-12A Phase II, Opened, Not Controlled and Multicentric Clinical Trial of Pazopanib in Monotherapy to Determine Efficiency and Safety in Second-line of Treatment in Patients With Carcinoma of Advanced Renal Cells That Have Progressed or Have Not Tolerated the First Line of Treatment With Tyrosine Kinase Inhibitor
-
CLINICAL_TRIALS study record update · 2014-02-06Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment
-
CLINICAL_TRIALS study record update · 2014-01-29Serum Carbonic Anhydrase 9 (CA9) Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer : a Pilot Study